Mighty Oak Medical v. Medacta: Patient-Matched Surgical Guide IP Settled After 622 Days
Mighty Oak Medical filed suit in Delaware District Court against Medacta International and Medacta USA, asserting five patents covering patient-matched surgical guides and instruments. The parties reached a confidential settlement, securing dismissal with prejudice after 622 days of litigation — with each side bearing its own costs.
Five-Patent Surgical Guide Dispute Ends in Confidential Settlement
Mighty Oak Medical, Inc., a company holding patents on patient-matched surgical guide technology, filed suit on 22 December 2022 in the District of Delaware against Medacta International SA (Switzerland) and its US subsidiary Medacta USA, Inc. The complaint asserted five patents — US8758357B2, US8870889B2, US9987024B2, US9642633B2, and US9198678B2 — covering patient-matched apparatus, surgical guides, and methods for performing orthopaedic procedures, directed at Medacta’s competing product line.
The case terminated on 4 September 2024 when Judge Jennifer L. Hall entered dismissal with prejudice pursuant to a joint motion under Fed. R. Civ. P. 41(a)(2). The parties had entered into a Settlement Agreement, Release, and License on 30 August 2024. Dismissal with prejudice bars Mighty Oak from re-filing the same claims against Medacta, but the court retained jurisdiction to enforce the settlement — consistent with the license grant indicating ongoing commercial terms between the parties.
At 622 days, the case ran longer than a simple early-stage dismissal would suggest, indicating substantive motion practice or claim construction activity before the parties reached resolution. The inclusion of a License in the settlement instrument suggests Medacta may have secured a right to continue operating in the patient-matched surgical guide space under defined terms. Financial terms and royalty structures, if any, remain undisclosed from the public record.
Filing to Dismissed with Prejudice in 622 days
622 days litigated — above the median for patent cases in Delaware District Court
Dismissed with prejudice: what the settlement and license mean for both parties
Rule 41(a)(2) dismissal with prejudice — a final resolution
A Rule 41(a)(2) dismissal with prejudice, entered by court order, constitutes a final adjudication on the merits as a matter of law. Unlike a voluntary dismissal without prejudice, this bars Mighty Oak from reasserting these same patent claims against Medacta in any future proceeding. The court’s retention of jurisdiction to enforce settlement terms is standard where a license is part of the resolution.
No re-filing permittedMighty Oak secures a settlement — likely with licensing upside
The dismissal with prejudice, combined with a Settlement Agreement, Release, and License, suggests Mighty Oak achieved a commercial resolution rather than a straight defeat. The explicit reference to a License in the court filing indicates Medacta acknowledged the patents to a degree sufficient to negotiate ongoing use rights. The five patents remain enforceable against third parties not party to this settlement.
Patents remain live vs. othersMedacta obtains finality and likely a license to continue operations
Medacta’s agreement to a dismissal with prejudice — rather than pursuing invalidity rulings — suggests the commercial value of a licensed path forward outweighed the cost and risk of continued litigation. The Release eliminates future infringement exposure from Mighty Oak on these five patents. Each party bearing its own costs is a neutral cost-allocation consistent with a negotiated settlement rather than a plaintiff capitulation.
License secured, exposure releasedPatient-matched surgical guide IP remains a live enforcement landscape
Mighty Oak’s five patents survive this litigation intact and enforceable against the broader market. Competitors in patient-specific instrumentation — particularly those offering spine or orthopaedic patient-matched guides — should note that this portfolio has demonstrated willingness to litigate to the 22-month mark before licensing. Other device makers operating in this space cannot rely on the Medacta settlement as a precedent affecting their own exposure.
Portfolio remains activeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Mighty Oak Medical, Inc. | Company | Medical device IP company — holder of US8758357B2 and 4 related patient-matched surgical guide patentsSearch in Eureka ↗ |
| Defendant | Medacta International, SA | Company | Swiss orthopaedic device manufacturer and its US commercial subsidiarySearch in Eureka ↗ |
| Co-Defendant | Medacta USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Adam M. Kaufmann | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | AnnaMartina Tyreus Hufnal | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brandon J. Pakkebier | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chad S.C. Stover | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ian Walsworth | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason M. Zucchi | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Todd G. Vare | Attorney | Counsel for Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Barnes & Thornburg LLP | Law Firm | Representing Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Cirrus Aircraft | Law Firm | Representing Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fish & Richardson PC | Law Firm | Representing Mighty Oak Medical, Inc.Search in Eureka ↗ |
| Defendant counsel | Amy Michele Dudash | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant counsel | Jason C. White | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant counsel | Karon N. Fowler | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant counsel | Kevin J. Spinella | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant counsel | Michael T. Sikora | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant counsel | Nicholas A. Restauri | Attorney | Counsel for Medacta International, SASearch in Eureka ↗ |
| Defendant law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Medacta International, SASearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text reflects a joint Rule 41(a)(2) motion — both parties requesting dismissal with prejudice together — which is procedurally distinct from a unilateral abandonment. The explicit reference to a ‘Settlement Agreement, Release, and License’ confirms this is a negotiated commercial resolution. The court’s retained jurisdiction clause is a standard drafting mechanism to allow either party to seek enforcement of the license terms without re-filing, indicating the parties anticipate an ongoing commercial relationship governed by the settlement instrument.
US8758357B2 and portfolio — patient-matched orthopaedic surgical guides
The five asserted patents — US8758357B2, US8870889B2, US9987024B2, US9642633B2, and US9198678B2 — form a portfolio covering patient-matched surgical guides and related methods. Patient-matched (or patient-specific) instrumentation uses pre-operative imaging data, typically CT or MRI, to manufacture custom-fit guides that align precisely with a patient’s unique anatomy. Applications include spinal surgery, joint replacement, and orthopaedic bone-cutting procedures. The patents span application dates from 2011 through 2017, reflecting iterative innovation across the product lifecycle.
Patient-specific instrumentation is a high-growth segment within surgical robotics and orthopaedics, with multiple large-device makers competing for market share. A portfolio covering both the apparatus and the methods of use provides broad claim coverage — apparatus claims capture the physical guide, while method claims capture the surgical technique, together making design-arounds substantially more difficult. Mighty Oak’s willingness to assert all five patents simultaneously against a well-funded international defendant signals confidence in the portfolio’s strength and breadth.
Should your team run an FTO against Mighty Oak Medical’s surgical guide portfolio?
Any company developing, manufacturing, or commercialising patient-matched or patient-specific surgical guides — including spine, hip, knee, or shoulder applications — should conduct a freedom-to-operate analysis against US8758357B2, US8870889B2, US9987024B2, US9642633B2, and US9198678B2. The Medacta case confirms this portfolio is actively enforced. Both apparatus and method claims are in play, meaning product design-arounds must account for the surgical workflow, not just the physical instrument.
PatSnap Eureka’s FTO Search Agent can map all five Mighty Oak patents against your product’s technical features, identify claim elements posing infringement risk, and surface prior art that could support invalidity arguments. Given the multi-patent structure of this portfolio, Eureka’s side-by-side claim comparison and citation analysis tools are particularly suited to scoping the risk efficiently before market entry or product launch.
Run a freedom-to-operate analysis on US8758357B2 to assess your product’s exposure
Run FTO in Eureka →Similar patient-matched surgical device patent cases in Delaware District Court
Explore related patent infringement actions involving patient-specific orthopaedic instrumentation and surgical guide technology litigated in the District of Delaware.
What this case signals for the patient-matched surgical device IP landscape
A five-patent assertion, 622-day litigation cycle, and license outcome points to a maturing and assertive IP enforcement posture in surgical guide technology.
Mighty Oak’s portfolio is active and has proven litigation-ready
With five issued patents asserted and a case lasting over 20 months before settlement, Mighty Oak has demonstrated it will sustain prolonged litigation to enforce its patient-matched surgical guide IP. Competitors should treat this portfolio as a live enforcement risk, not a paper threat.
A license in the settlement signals commercial value, not just legal closure
The explicit license grant in the settlement instrument suggests Medacta continues operating in the patient-matched surgical guide space under terms agreed with Mighty Oak. This pattern — litigate, then license — is a classic monetisation strategy that may be repeated against other market participants.
Mighty v Medacta — key questions answered
Mighty Oak Medical asserted five US patents: US8758357B2, US8870889B2, US9987024B2, US9642633B2, and US9198678B2. All five cover patient-matched surgical guides and related methods for performing orthopaedic surgical procedures. The case was filed in the District of Delaware on 22 December 2022.
The case was dismissed with prejudice on 4 September 2024 under Fed. R. Civ. P. 41(a)(2), following a joint motion by both parties. Dismissal with prejudice means Mighty Oak cannot re-file the same patent claims against Medacta. The parties entered a Settlement Agreement, Release, and License, with each party bearing its own costs.
No. The settlement and release are bilateral — they bind only Mighty Oak and the two Medacta entities named in the case. All five asserted patents remain valid and enforceable against third parties. Other companies in the patient-matched surgical guide market retain independent exposure to these patents.
Patient-matched surgical guides are custom-fabricated instruments manufactured from a patient’s pre-operative CT or MRI imaging data. They fit precisely to individual anatomy, improving surgical accuracy. The technology sits at the intersection of medical imaging, CAD/CAM manufacturing, and orthopaedic surgery, generating valuable IP that multiple competitors seek to develop and commercialise, making infringement disputes common.
Delaware is the most common venue for US patent infringement actions involving incorporated defendants, as a large proportion of US companies — including many medical device firms — are incorporated in Delaware. The district has experienced patent judges and established local patent rules, making it a preferred choice for plaintiffs asserting multi-patent portfolios against well-funded defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.